Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Drugs.com MedNews
Links shared publicly online about this topic.
- 95total visits
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Drugs.com MedNews
View full resource at drugs.com
Most Recently Shared on August 5, 2011 at 1:06 pm By:
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Fol... http://bit.ly/p1ft6q #drug
Amylin And Takeda Discontinue Development Of
pharmaceuticalonline.com — “Amylin And Takeda Discontinue Development Of Pramlintide/Metreleptin Combination Treatment For Obesity Following Commercial Reassessment Of The Program - Amylin Pharmaceuticals” View full resource at pharmaceuticalonline.com
Most Recently Shared on August 8, 2011 at 5:22 pm By:
Amylin And Takeda Discontinue Development Of Pramlintide/Metreleptin Combination Treatment For Obesity Following... http://bit.ly/qIIhxi
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program - Health News - redOrbit
redorbit.com — “SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- OSAKA, Japan, Aug. 5, 2011 -- Amylin Pharmaceuticals, Inc.” View full resource at redorbit.com
Most Recently Shared on August 5, 2011 at 4:53 am By:
Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following... http://bit.ly/pnUdb1
Advertisement
